RE: Sad news about Dr. Ludden
We're very fortunate in this field to have an abundance or leaders who seem
entirely motivated by advancing the field and helping others with their
professional development. In my limited experience, more so than any other
field of bio medial research. Few however were as patient and generous as Tom.
Many in this group are probably aware of the story of how he came to have
NONMEM license #1 and how he was one of the few who gained Stuart's trust and
respect early in the history of PMX, and the critical role he played in bring
these methods into mainstream pharmaceutical research, a testament to both his
technical knowledge and leadership skills. Like many others I personally
benefited from my interactions with him.
Mark
Mark Sale M.D.
Vice President
Integrated Drug Development
[email protected]
Remote-Forestville CA
Office Hours 9 AM - 5 PM Eastern Time
+1 302-516-1684
www.certara.com
[Certara Logo]
Quoted reply history
From: [email protected] <[email protected]> On Behalf Of
Nick Holford
Sent: Saturday, August 3, 2024 1:20 AM
To: [email protected]
Subject: RE: [NMusers] Sad news about Dr. Ludden
CAUTION: This email originated from outside of Certara. Do not click links or
open attachments unless you recognize the sender and know the content is safe.
Thanks to nmusers for informing me of this sad news. I have known Tom for many
years but we only occasionally met face to face. I echo the sentiments of
others below who spoke of his depth of knowledge and gentleness. He helped me
many times when I was struggling with NONMEM and I think we always found a
solution. We wrote one publication together, a book chapter on the "Time Course
of Drug Effect". This echoed what is my earliest citation of Tom's scientific
contributions nearly 40 years age (Svec JM, Coleman RW, Mungall DR, Ludden TM.
Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to
warfarin therapy: preliminary evaluation. Ther Drug Monit. 1985;7(2):174-80.).
Tom, I hope in your afterlife you will still be able to follow nmusers. Thank
you for all you have given to so many of us.
--
Nick Holford, Professor Emeritus Clinical Pharmacology, MBChB, FRACP
mobile: NZ+64(21) 46 23 53 ; FR+33(6) 62 32 46 72
email: [email protected]<mailto:[email protected]>
web: http://holford.fmhs.auckland.ac.nz/
From: [email protected]<mailto:[email protected]>
<[email protected]<mailto:[email protected]>> On Behalf
Of Patel, Bela
Sent: Saturday, August 3, 2024 1:43 AM
To: ENE ETTE <[email protected]<mailto:[email protected]>>; Diane
Mould <[email protected]<mailto:[email protected]>>; Riley, Steve
<[email protected]<mailto:[email protected]>>;
[email protected]<mailto:[email protected]>
Subject: RE: [External email][NMusers] Sad news about Dr. Ludden
Some people who received this message don't often get email from
[email protected]<mailto:[email protected]>. Learn why this is
https://aka.ms/LearnAboutSenderIdentification
Public
Dear All,
I am extremely saddened to hear this news. As mentioned by Ene, Dr. Tom Ludden
was one of the pioneers in advancing pharmacometrics along with Dr. Beal and
Dr. Sheiner promoting its value and impact in drug discovery and development as
well as acceptance by the FDA. He provided invaluable scientific advice and
trained numerous scientists in pharmacometrics. He was a real gentle soul and
it was truly a privilege to have known him and be tutored by him.
May his soul rest in peace.
Sincerely,
Bela
From: [email protected]<mailto:[email protected]>
<[email protected]<mailto:[email protected]>> On Behalf
Of ENE ETTE
Sent: Friday, August 2, 2024 5:30 PM
To: Diane Mould <[email protected]<mailto:[email protected]>>; Riley,
Steve <[email protected]<mailto:[email protected]>>;
[email protected]<mailto:[email protected]>
Subject: RE: [External email][NMusers] Sad news about Dr. Ludden
Some people who received this message don't often get email from
[email protected]<mailto:[email protected]>. Learn why this is
https://aka.ms/LearnAboutSenderIdentification
EXTERNAL EMAIL- Use caution with any links or file attachments.
Dear All:
In Dr. Ludden we lost an excellent scientist who helped to revolutionize and
advance clinical pharmacokinetics, pharmacometrics, clinical pharmacology, and
drug development. I'm indebted to him for the impact he made on my life as a
pharmacometrician, clinical pharmacologist, and drug developer while working
with him at the FDA. He started the Pharmacometrics Staff Unit which became
Pharmacometrics Division in later years.
May his soul rest in peace.
Sincerely,
Ene.
Sent from https://go.microsoft.com/fwlink/?LinkId=550986 for Windows
From: Diane Mould<mailto:[email protected]>
Sent: Friday, August 2, 2024 4:03 PM
To: Riley, Steve<mailto:[email protected]>;
[email protected]<mailto:[email protected]>
Subject: RE: [External email][NMusers] Sad news about Dr. Ludden
Dear All
I am very saddened to hear this news. Tom Ludden was one of the nicest and
smartest people that I have ever known. He was a gentle giant in our field and
I will miss him.
Best
Diane
From: [email protected]<mailto:[email protected]>
<[email protected]<mailto:[email protected]>> On Behalf
Of Riley, Steve
Sent: Friday, August 2, 2024 2:41 PM
To: [email protected]<mailto:[email protected]>
Subject: [External email][NMusers] Sad news about Dr. Ludden
CAUTION: This email originated from outside the organization. Do not click
links or open attachments unless you recognize the sender and know the content
is safe.
Dear NM-Users,
Regrettably, I am writing to let you know that Dr. Ludden passed away Tuesday
evening, 30JUL2024.
I was able to get there over the weekend prior to visit him and his family.
During his wakeful moments we had some good scientific discussions.
We talked a lot about NONMEM and how its functionality and utility has expanded
since he retired. He was pleased to hear about the changes.
He was surrounded by family for the days leading up to the end. They were all
appreciative that I was able to get there and tell him (and them) how much he
meant to all of us and the impact he had on our careers.
I think memories of Dr. Ludden were characterized perfectly by Marc Gastonguay,
"I am forever grateful for the positive impact that Tom had on my life and
career, not to mention the tremendous, although often underappreciated,
contributions he made to the disciplines of clinical pharmacology and
pharmacometrics. His humble brilliance will be missed and fondly remembered."
Steve Riley
This e-mail message, together with any attachments, contains information of
Merck & Co., Inc. (126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ USA 07065)
and/or its affiliates, that may be confidential, proprietary copyrighted and/or
legally privileged. (Direct contact information for affiliates is available
at - Contact us - https://www.msd.com/contact-us/.) It is intended solely
for the use of the individual or entity named on this message. If you are not
the intended recipient, and have received this message in error, please notify
us immediately by reply e-mail and then delete it from your system.
This message (including any attachments) may contain confidential, proprietary,
privileged and/or private information. The information is intended to be for
the use of the individual or entity designated above. If you are not the
intended recipient of this message, please notify the sender immediately, and
delete the message and any attachments. Any disclosure, reproduction,
distribution or other use of this message or any attachments by an individual
or entity other than the intended recipient is prohibited.